Healthy Returns: 2026 will be the year of obesity pills from Novo Nordisk, Eli Lilly
2026 is likely the year that two new oral weight loss drugs from Novo Nordisk and Eli Lilly will reach patients in the U.S.
NVO - Novo Nordisk A/S
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$55.00
DETAILS
HIGH:
$70.00
LOW:
$47.00
MEDIAN:
$51.50
CONSENSUS:
$55.00
DOWNSIDE:
11.76%
Stock News
Novo Nordisk Loses Momentum As Eli Lilly Pulls Ahead In Weight-Loss Wars
Novo Nordisk A/S (NYSE: NVO) stock has plunged around 41% year to date, as per data from Benzinga Pro.
Novo Nordisk A/S $NVO Shares Sold by Corient Private Wealth LLC
Corient Private Wealth LLC cut its stake in shares of Novo Nordisk A/S (NYSE: NVO) by 6.5% during the second quarter, according to the company in its most recent filing with the Securities and...
Final Trade: JNJ, NVO, UBER, BMY
The final trades of the day with CNBC's Melissa Lee and the 'Fast Money' traders.
CHMP Backs Higher-Dose Wegovy as Novo Nordisk Seeks 2026 EU Approval
NVO gains CHMP backing for a higher-dose Wegovy, paving the way for potential EU approval in 2026 as study data show stronger weight loss.
Investors Heavily Search Novo Nordisk A/S (NVO): Here is What You Need to Know
Recently, Zacks.com users have been paying close attention to Novo Nordisk (NVO). This makes it worthwhile to examine what the stock has in store.
2 Predictions for Novo Nordisk in 2026
Novo Nordisk has the potential to maintain more consistent revenue growth throughout next year. There is an indication that the company's pipeline candidates will see strong progress in 2026.
European Regulator Backs Approval Of Novo Nordisk High-Dose Wegovy
EMA issues positive opinion on Novo Nordisk's higher-dose Wegovy, supported by strong weight-loss data and ongoing reviews in the U.S., U.K., and other markets.
Novo's Next Shot at Dominance: High-Dose Wegovy Takes Aim at Lilly's Zepbound
Novo Nordisk (NVO) said its high-dose version of Wegovy has received a positive recommendation from the European Union's drug advisory board, potentially openin
NVO Down 42% Year to Date: Is This an Indication to Sell the Stock?
Novo Nordisk stock plunges 42% so far in 2025 as GLP-1 competition, price cuts, guidance trims and restructuring plans cloud growth and elevate execution risks.
EU drugs regulator backs higher dose of Novo's Wegovy
Novo Nordisk said on Friday the European Medicines Agency's committee has issued a positive opinion for a 7.2 mg dose of weight-loss drug Wegovy, providing an option for greater weight loss.
Novo Nordisk A/S: More efficacious dose of Wegovy® recommended by the European Medicines Agency can help people with obesity achieve an average of 20.7% weight loss
The European Medicines Agency (EMA) has issued a positive opinion for a new Wegovy® 7.2 mg dose, advancing its availability in the European Union (EU)
Novo Nordisk Launches $24 a Week Ozempic in This Country. Why the Big Price Cut.
Americans without health insurance could be paying more than 10 times as much for the weight-loss drugs.
Novo Nordisk Launches Ozempic in India at $24 a Week
Novo Nordisk (NVO, Financials) has brought its blockbuster diabetes medicine Ozempic to India, where the lowest weekly dosage costs around $24. The company hope
Novo Nordisk launches blockbuster diabetes drug Ozempic in India
Danish drugmaker Novo Nordisk launched its blockbuster diabetes drug Ozempic in India on Friday.
Why Novo Nordisk Stock Topped the Market on Thursday
A bipartisan bill has been introduced in the U.S. Congress that would curb some activities of compound pharmacies. The maker of Wegovy has been particularly affected by competition from such parties.
Novo Nordisk (NVO) Laps the Stock Market: Here's Why
Novo Nordisk (NVO) closed at $50.29 in the latest trading session, marking a +2.53% move from the prior day.
Market Today: Fed Cut, Oracle Slide, Broadcom AI Surge
Stock News Oracle sinks, ripples across AI trade: Oracle (ORCL) fell about 11% after a revenue miss and heavier AI capex drove negative free cash flow, pressuri
Danish weight loss drug maker outlines ambitious 2030 strategy, ramping up pressure on Novo, Lilly
Ahead of its Capital Markets Day Thursday, Zealand Pharma unveiled its "Metabolic Frontier 2030" strategy. The strategy comes as Zealand shares have dropped 29% year to date, with investors...
3 Absurdly Cheap Stocks That Look Like Steals Right Now
UPS, Novo Nordisk, and Adobe are all trading well below the S&P 500's average price-to-earnings ratio. Their underlying businesses are solid and profitable.
Price Targets
Novo Nordisk price target raised to $55 from $50 at BMO Capital
$55.00
(was $57.50)
Evan Seigerman
·
BMO Capital
Novo Nordisk upgraded to Buy from Hold at HSBC
$70.00
(was $59.17)
HSBC
Novo Nordisk downgraded to Underweight from Equal Weight at Morgan Stanley
$47.00
(was $55.61)
Morgan Stanley
Novo Nordisk downgraded to Hold from Buy at HSBC
$57.00
(was $48.88)
HSBC
What's Going On With Hims & Hers Stock Wednesday?
$48.00
(was $70.03)
Jailendra Singh
·
Truist Financial
Novo Nordisk price target lowered to $156 from $160 at BMO Capital
$156.00
(was $118.58)
Evan Seigerman
·
BMO Capital
Cantor Fitzgerald on Novo Nordisk (NVO): 'These data compare favorably to other orals in development'
$160.00
(was $135.23)
Louise Chen
·
Cantor Fitzgerald
Novo Nordisk (NVO) PT Lowered to $160 at BMO Capital
$160.00
(was $126.17)
Evan David Seigerman
·
BMO Capital
Novo Nordisk price target raised to $160 from $125 at Argus
$160.00
(was $142.88)
Jasper Hellweg
·
Argus Research
Novo Nordisk initiated with a Buy at Goldman Sachs
$156.00
(was $132.68)
James Quigley
·
Goldman Sachs
BMO Capital Starts Novo Nordisk (NVO) at Outperform
$163.00
(was $125.40)
Evan David Seigerman
·
BMO Capital